Related Experiment Video
Updated: Nov 4, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Potential role of circular RNA in cyclosporin A-induced cardiotoxicity in rats
Yanru Zhao1, Yang Li1, Dachuan Fan2
1Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
Insights
Cyclosporin A causes heart toxicity, but circular RNAs (circRNAs) may offer new therapeutic targets. This study identified specific circRNA changes linked to this toxicity, suggesting potential diagnostic and treatment avenues.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Toxicology
Background:
- Cyclosporin A (CsA) is vital for autoimmune diseases and transplants but causes cardiotoxicity.
- Circular RNAs (circRNAs) are implicated in cardiovascular disease pathogenesis.
- Understanding CsA's cardiotoxic mechanisms is crucial for patient safety.
Purpose of the Study:
- To investigate circRNA expression profiles in CsA-induced cardiotoxicity.
- To identify potential molecular mechanisms underlying CsA cardiotoxicity.
- To explore circRNAs as biomarkers or therapeutic targets for CsA cardiotoxicity.
Main Methods:
- Wistar rats were treated with CsA (15 mg/kg/day) or olive oil for two weeks.
- Cardiotoxicity was assessed using microscopy and TUNEL staining.
- circRNA expression was analyzed via microarray, with validation by qRT-PCR.
- Gene Ontology and KEGG pathway analyses were performed on differentially expressed circRNAs.
Main Results:
- CsA induced significant cardiotoxicity in rats.
- Microarray analysis revealed 104 differentially expressed circRNAs (67 upregulated, 37 downregulated).
- Quantitative real-time PCR confirmed changes in 6 of 12 tested circRNAs.
- Pathway analysis suggested involvement of autophagy and Hippo signaling.
Conclusions:
- CsA-induced cardiotoxicity is associated with distinct circRNA expression patterns.
- Differentially expressed circRNAs may mediate CsA cardiotoxicity via autophagy or Hippo signaling.
- circRNAs represent promising future biomarkers and therapeutic targets for CsA cardiotoxicity.
Abstract:
Cyclosporin A (CsA) is a well-known and effective drug that is commonly used in autoimmune diseases and allotransplantation. However, kidney toxicity and cardiotoxicity limit its use. Circular RNAs (circRNAs) play a crucial role in disease, especially cardiovascular disease. We aimed to explore the circRNA expression profiles and potential mechanisms during CsA-induced cardiotoxicity. Sixty male adult Wistar rats were randomly divided into two groups. The CsA group was injected with CsA (15 mg/kg/day body weight) intraperitoneally (ip) for 2 weeks, whereas the control group was injected ip with the same volume of olive oil. We assessed CsA-induced cardiotoxicity by light microscopy, transferase-mediated dUTP nick-end labeling (TUNEL) staining, and electron microscopy. Microarray analysis was used to detect the expression profiles of circRNAs deregulated in the heart during CsA-induced cardiotoxicity. We confirmed the changes in circRNAs by quantitative PCR. Moreover, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of the microarray data were performed. A conventional dose of CsA induced cardiotoxicity in rats. We identified 67 upregulated and 37 downregulated circRNAs compared with those in the control group. Six of 12 circRNAs were successfully verified by quantitative real-time polymerase chain reaction (qRT-PCR). GO analyses of the differentially expressed circRNAs indicated that these molecules might play important roles in CsA-induced cardiotoxicity. KEGG pathway analyses showed that the differentially expressed circRNAs in CsA-induced cardiotoxicity may be related to autophagy or the Hippo signaling pathway. We identified differential circRNA expression patterns and provided more insight into the mechanism of CsA-induced cardiotoxicity. CircRNAs may serve as potential biomarkers or therapeutic targets of CsA-mediated cardiotoxicity in the future.
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Rheumatic Heart Disease I: Introduction
Heart Failure Drugs: Inotropic Agents

